Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.20157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von P V Chernyshov und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, National Medical University, Kiev, Ukraine. Hauptthemen laut MEDLINE: Quality of Life, Angioedema, Urticaria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 332 Literaturangaben.
Abstract (Originalsprache)
The European Academy of Dermatology and Venereology (EADV) Task Forces on quality of life (QoL) and patient‐oriented outcomes and on urticaria and angioedema recommendations for the assessment of Health‐related (HR) QoL in all patients with urticaria in research and practice are as follows: to use the DLQI for adults and the CDLQI for children as dermatology‐specific and the CU‐Q2oL as a disease‐specific HRQoL instruments in urticaria; to use generic instruments to provide comparison of data on urticaria with non‐dermatologic diseases, or to compare with healthy volunteers or the general population; to select validated HRQoL instruments with appropriate age limits; to present exact numeric data for HRQoL results; correct title of any HRQoL instrument should be used, along with its correct abbreviation and the reference to its original publication, where possible. The EADV TFs discourage the use of non‐validated HRQoL instruments and modified HRQoL instruments that have not undergone standard validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology and Venereology, National Medical University, Kiev, Ukraine.
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
- Department of Psychology, University of Zaragoza, Zaragoza, Spain.
- Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
- Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey.
ORCID-Profile: P V Chernyshov, A Y Finlay, T Zuberbier, A Svensson, F Sampogna, A Bewley, D Koumaki, M Augustin, D Linder, S S Salek, J Szepietowski
Zitieren
APA
Chernyshov, P. V., Finlay, A. Y., Tomas-Aragones, L., Zuberbier, T., Kocatürk, E., Manolache, L., Pustisek, N., Svensson, A., Marron, S. E., Sampogna, F., Bewley, A., Salavastru, C., Koumaki, D., Augustin, M., Linder, D., Abeni, D., Salek, S. S., Szepietowski, J., & Jemec, G. B. (2024). Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20157
Vancouver
Chernyshov PV, Finlay AY, Tomas-Aragones L, Zuberbier T, Kocatürk E, Manolache L, et al. Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.20157
BibTeX
@article{Chernyshov2024,
author = {Chernyshov, P V and Finlay, A Y and Tomas-Aragones, L and Zuberbier, T and Kocatürk, E and Manolache, L and Pustisek, N and Svensson, A and Marron, S E and Sampogna, F and Bewley, A and Salavastru, C and Koumaki, D and Augustin, M and Linder, D and Abeni, D and Salek, S S and Szepietowski, J and Jemec, G B},
title = {Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.20157}
}
EUVIMED